Paclitaxel-Coated Devices in Chronic Limb-Threatening Ischemia
A recent study investigated the effectiveness of paclitaxel-coated devices in reducing rates of major amputations in patients with chronic limb-threatening ischemia.
The study found that all-cause mortality and reduction in major amputations were similar between groups, with no significant difference in the rate of target vessel reintervention at 5 years.
The impact of drug-coated devices on amputation risk in peripheral artery disease remains unclear.
Key Findings
- The primary outcome was ipsilateral major amputation (above the ankle).
- A key secondary outcome was all-cause mortality.
- The rate of target vessel reintervention was similar in paclitaxel-coated and uncoated devices groups at 5 years.
Evidence Rating Level: 1 (Excellent)
Author's summary: Paclitaxel-coated devices do not reduce amputation rates.
More News
- The End of Eurobike? Who Will Lead the Bike Industry Now?
- Distorted narratives risk reversing South Caucasus peace progress [OPINION]
- The power of organising and how to win the outsourcing battle | Article | News | UNISON National
- ICE Plans Cash Rewards for Private Bounty Hunters to Locate and Track Immigrants